

Cancel claims 1-10. Insert new claims 11-24.

--11. A method for identifying a compound that modulates an FKHL7 bioactivity, comprising the steps of:

(a) contacting an appropriate amount of the compound with a cell or cellular extract, which expresses an FKHL7 gene; and

(b) determining the resulting FKHL7 bioactivity, wherein an increase or decrease in the FKHL7 bioactivity in the presence of the compound as compared to the bioactivity in the absence of the compound indicates that the compound is a modulator of an FKHL7 bioactivity.

12. The method of claim 11, wherein the compound is an agonist of an FKHL7 bioactivity.

13. The method of claim 11, wherein the compound is an antagonist of an FKHL7 bioactivity.

14. A compound that has been identified according to the method of claim 11.

15. The method of claim 11, wherein the compound is a member selected from the group comprising a polypeptide, a nucleic acid, a peptidomimetic, and a small molecule.

16. The method of claim 11, wherein the small molecule is a steroid.

17. The method of claim 11, wherein the nucleic acid is a member selected from the group consisting of a gene replacement, an antisense, a ribozyme, and a triplex nucleic acid.

18. A method for identifying a compound that modulates an FKHL7 bioactivity comprising the steps of:

(a) combining an FKHL7 protein, an FKHL7 binding partner, and a test compound under conditions wherein, but for the test compound, the FKHL7 protein and FKHL7 binding partner are able to interact; and

(b) detecting the formation of an FKHL7 protein/FKHL7 binding partner complex, such that a difference in the formation of an FKHL7 protein/FKHL7 binding partner complex in the presence of a test compound relative to in the absence of the test compound indicates that the test compound is an FKHL7

therapeutic.

19. The method of claim 18, wherein the compound is a member selected from the group comprising a polypeptide, a nucleic acid, a peptidomimetic, and a small molecule.
20. The method of claim 18, wherein the small molecule is a steroid.
21. The method of claim 18, wherein the nucleic acid is a member selected from the group consisting of a gene replacement, an antisense, a ribozyme, and a triplex nucleic acid.
22. The method of claim 18, wherein the compound is an agonist of an FKHL7 bioactivity.
23. The method of claim 18, wherein the compound is an antagonist of an FKHL7 bioactivity.
24. A compound that has been identified according to the method of claim 18.

CONCLUSION

Applicants respectfully request consideration of the claims and prompt allowance of the claims. The Commissioner is authorized to charge any under-payments or credit any over-payments to our Deposit Account No.06-1448.

Respectfully submitted,
FOLEY, HOAG, & ELIOT


Beth E. Arnold
Reg. No. 35,430

Date: July 10, 2000

Patent Group
Foley, Hoag & Eliot LLP
One Post Office Square
Boston, MA 02109-2170
Tel: (617) 832-1000
FAX: (617) 832-7000